S&P Futures
4,107.25-12.25(-0.30%)Dow Futures
33,578.00-104.00(-0.31%)Nasdaq Futures
13,789.50-40.00(-0.29%)
Tetra Bio-Pharma Inc. (TBP.TO)
Tetra Bio-Pharma Inc.
2316 St. Joseph Boulevard
Orléans, ON K1C 1E8
Canada
343 780 2020
http://www.tetrabiopharma.com
Sector(s):Â Healthcare
Industry:Â Biotechnology
Full Time Employees:Â
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Guy Chamberland M.Sc., Master Herbal, Ph.D. | Co-Founder, CEO, Chief Regulatory Officer & Director | 294.8k | N/A | 1962 |
| Mr. André Rancourt B.Sc. | Co-Founder | N/A | N/A | N/A |
| Mr. Jean-Francois Boily C.A., CPA | Chief Financial Officer | N/A | N/A | N/A |
| Dr. Graham Wood | Chief Operating Officer | N/A | N/A | N/A |
| Dr. Melanie Edna Mary Kelly Ph.D. | Chief Scientific Officer | N/A | N/A | N/A |
| Jennifer McCaughey | VP of Investor Relations | N/A | N/A | N/A |
| Mr. Steeve Néron | Chief Commercial Officer | N/A | N/A | N/A |
| Ms. Dania Scott B.Sc. | Sr. VP of Commercial Strategy | N/A | N/A | N/A |
| Mr. Richard Giguere | Chief Exec. Officer of Tetra Natural Health Inc. | N/A | N/A | N/A |
| Randy Ringuette | Project Director & Member of Advisory Board | N/A | N/A | N/A |
Description
Tetra Bio-Pharma Inc., a development stage biopharmaceutical company, engages in the discovery and development of immunomodulator drugs. It develops ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; Reduvo for chemotherapy-induced nausea and vomiting; PLENITUDE to treat advanced uncontrolled cancer pain; REBORN for the treatment of breakthrough cancer pain and fibromyalgia; and SERENITY to treat cancer cachexia. The company also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma. Tetra Bio-Pharma Inc. is headquartered in Orleans, Canada.
Corporate Governance
Tetra Bio-Pharma Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
